Blog

CM hyperlipidemia

Here are the current (ACC/AHA-based) practical hyperlipidemia guidelines in a way that matches how you’ll actually use them in primary care / correctional medicine.

I’ll focus on:

  1. when to treat
  2. statin intensity (first-line)
  3. 2nd line
  4. 3rd line / add-ons
  5. special populations and targets

1. Current Guideline Framework (ACC/AHA 2018 + updates)

Modern lipid management is risk-based, not LDL-target-based for most patients.

You treat based on 4 main groups:

1) Clinical ASCVD (secondary prevention)

Examples:

  • prior MI
  • stroke/TIA
  • PAD

➡️ Treat aggressively.

2) LDL ≥190 mg/dL (severe hypercholesterolemia)

➡️ Treat regardless of risk score.

3) Diabetes age 40–75

➡️ At least moderate-intensity statin
➡️ High-intensity if higher risk

4) Primary prevention (no ASCVD/diabetes)

Use 10-year ASCVD risk:

  • low <5% → lifestyle
  • borderline 5–7.5% → consider statin
  • intermediate 7.5–20% → statin recommended
  • high ≥20% → high-intensity statin

2. First-Line Therapy: STATINS (Core Treatment)

Statins are still the foundation of therapy.

They reduce:

  • LDL
  • MI risk
  • stroke risk
  • mortality

High-Intensity Statins (↓ LDL ≥50%)

These are first-line for:

  • ASCVD
  • LDL ≥190
  • high-risk diabetics

Recommended high-intensity statins:

  • Atorvastatin 40–80 mg
  • Rosuvastatin 20–40 mg

These are the ONLY two routinely used high-intensity statins in the US.

Moderate-Intensity Statins (↓ LDL 30–49%)

Used for:

  • diabetes (most patients)
  • intermediate risk primary prevention
  • older patients or intolerance

Options:

  • Atorvastatin 10–20 mg
  • Rosuvastatin 5–10 mg
  • Simvastatin 20–40 mg
  • Pravastatin 40–80 mg
  • Lovastatin 40 mg
  • Fluvastatin XL 80 mg

Low-Intensity Statins (rarely used now)

  • Simvastatin 10 mg
  • Pravastatin 10–20 mg
  • Lovastatin 20 mg

➡️ Mostly obsolete in modern practice.

3. Treatment Targets (Practical Modern View)

Guidelines emphasize percentage LDL reduction, not strict LDL targets.

But clinically you still use thresholds:

High-risk ASCVD:

  • aim ≥50% LDL reduction
  • consider LDL <70 mg/dL reasonable goal

Very high-risk ASCVD:

(e.g., recurrent MI, multiple events)

  • consider LDL <55 mg/dL (European-style target used in practice)

4. When Statins Are Not Enough (Stepwise Therapy)

If LDL remains elevated on maximally tolerated statin:

2nd Line Therapy

1. Ezetimibe (Zetia) — FIRST ADD-ON

Mechanism:

  • inhibits intestinal cholesterol absorption

LDL reduction:

  • ~15–25%

When used:

  • ASCVD not at goal on statin
  • statin intolerance (partial)
  • very common add-on in real practice

Evidence:

  • improves outcomes when added to statins (IMPROVE-IT trial)

➡️ This is the standard second-line agent

3rd Line Therapy

If still not at goal after statin + ezetimibe:

2. PCSK9 inhibitors

Drugs:

  • Alirocumab
  • Evolocumab

LDL reduction:

  • ~50–60% additional reduction

When used:

  • very high-risk ASCVD
  • familial hypercholesterolemia
  • statin + ezetimibe failure
  • intolerance to statins

Notes:

  • injectable (every 2–4 weeks or monthly)
  • very effective but expensive

3. Inclisiran (siRNA therapy)

  • lowers PCSK9 production
  • dosing every 6 months after initial doses

Used when:

  • adherence is an issue
  • LDL still high despite therapy

4th Line / Special Situations

These are not routine but important in refractory cases:

Bempedoic acid

  • oral agent
  • works upstream of statins in cholesterol synthesis pathway

Useful in:

  • statin intolerance
  • combination therapy

LDL reduction:

  • ~15–25%

Recent outcome data supports benefit in statin-intolerant patients.

Bile acid sequestrants

Examples:

  • cholestyramine
  • colesevelam

Less used due to:

  • GI side effects
  • drug interactions

Niacin (rarely used now)

Once common, now rarely recommended due to:

  • minimal outcome benefit
  • side effects (flushing, hyperglycemia, hepatotoxicity)

5. Triglyceride Management (Important Adjunct)

Not primary LDL therapy, but often relevant.

Mild–moderate TG (150–499):

  • statin first
  • lifestyle

Severe TG ≥500:

goal is pancreatitis prevention:

  • fibrates
  • omega-3 fatty acids
  • very low-fat diet

6. Statin Intolerance Approach

If patient reports side effects:

Stepwise approach:

  1. stop statin briefly
  2. re-challenge
  3. switch statin (atorvastatin ↔ rosuvastatin)
  4. lower dose
  5. alternate-day dosing
  6. add ezetimibe if partial tolerance

True complete intolerance is uncommon.

7. Diabetes-Specific Recommendations

For age 40–75 with diabetes:

At minimum:

  • moderate-intensity statin

If additional risk factors:

  • high-intensity statin

Risk enhancers:

  • long duration diabetes
  • albuminuria
  • CKD
  • multiple ASCVD risk factors

8. Key “Correctional Medicine” Practical Points

In correctional settings you’ll see:

  • long gaps in medication access
  • inconsistent outpatient follow-up
  • untreated severe hyperlipidemia
  • polypharmacy issues
  • statin discontinuation on intake

Very common scenario:

Patient was on statin → enters facility → meds not continued → LDL rebounds

➡️ One of the most important correctional interventions is:
restarting appropriate statin therapy early

9. Summary: Stepwise Therapy Ladder

FIRST LINE

  • Statins (atorvastatin, rosuvastatin primarily)

SECOND LINE

  • Ezetimibe

THIRD LINE

  • PCSK9 inhibitors (alirocumab, evolocumab)
  • Inclisiran (selected cases)

FOURTH LINE / ADD-ONS

  • Bempedoic acid
  • bile acid sequestrants
  • (niacin rarely used)

Bottom Line

  • Statins are the foundation (high-intensity when possible)
  • Ezetimibe is the standard add-on
  • PCSK9 inhibitors are the most powerful escalation therapy
  • Modern guidelines emphasize risk-based treatment + % LDL reduction, not strict LDL targets alone

If you want, I can turn this into a correctional facility prescribing algorithm (what to do on intake day 1 vs follow-up) or a one-page cheat sheet for clinic use.